Drug Delivery Systems for the Oral Administration of Antimicrobial Peptides: Promising Tools to Treat Infectious Diseases

被引:34
作者
Deshayes, Caroline [1 ]
Arafath, Md. Nasir [2 ]
Apaire-Marchais, Veronique [1 ]
Roger, Emilie [2 ]
机构
[1] Univ Angers, INRAE, SIFCIR, SFR QUASAV, Angers, France
[2] Univ Angers, INSERM, CNRS, MINT,SFR ICAT, Angers, France
来源
FRONTIERS IN MEDICAL TECHNOLOGY | 2022年 / 3卷
关键词
oral route; antimicrobial peptides (AMPs); infectiology; pharmaceutical forms; drug delivery systems (DDS); LIPOSOME-ENCAPSULATED NISIN; IN-VITRO CHARACTERIZATION; ALGINATE MICROPARTICLES; VANCOMYCIN; BIOAVAILABILITY; NANOPARTICLES; RESISTANCE; EFFICACY; LFF571; FORMULATION;
D O I
10.3389/fmedt.2021.778645
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Antimicrobial peptides (AMPs) have a great potential to face the global expansion of antimicrobial resistance (AMR) associated to the development of multidrug-resistant (MDR) pathogens. AMPs are usually composed of 10-50 amino acids with a broad structural diversity and present a range of antimicrobial activities. Unfortunately, even if the oral route is the most convenient one, currently approved therapeutic AMPs are mostly administrated by the intravenous route. Thus, the development of novel drug delivery systems (DDSs) represents a promising opportunity to protect AMPs from chemical and enzymatic degradation through the gastrointestinal tract and to increase intestinal permeability leading to high bioavailability. In this review, the classification and properties as well as mechanisms of the AMPs used in infectiology are first described. Then, the different pharmaceutical forms existing in the market for oral administration are presented. Finally, the formulation technologies, including microparticle- and nanoparticle-based DDSs, used to improve the oral bioavailability of AMPs are reviewed.
引用
收藏
页数:13
相关论文
共 101 条
  • [1] Immunomodulatory Effect of Vancomycin on Treg in Pediatric Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
    Abarbanel, David N.
    Seki, Scott M.
    Davies, Yinka
    Marlen, Natalie
    Benavides, Joseph A.
    Cox, Kathleen
    Nadeau, Kari C.
    Cox, Kenneth L.
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (02) : 397 - 406
  • [2] Antimicrobial peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria
    Ageitos, J. M.
    Sanchez-Perez, A.
    Calo-Mata, P.
    Villa, T. G.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2017, 133 : 117 - 138
  • [3] Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials
    Aguirre, T. A. S.
    Teijeiro-Osorio, D.
    Rosa, M.
    Coulter, I. S.
    Alonso, M. J.
    Brayden, D. J.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2016, 106 : 223 - 241
  • [4] Oral drug delivery systems using chemical conjugates or physical complexes
    Al-Hilal, Taslim A.
    Alam, Farzana
    Byun, Youngro
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (06) : 845 - 864
  • [5] Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form
    Anderson, KE
    Eliot, LA
    Stevenson, BR
    Rogers, JA
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (03) : 316 - 322
  • [6] [Anonymous], 2015, GLOB ACT PLAN ANT RE, V10, P354, DOI DOI 10.1128/MICROBE.10.354.1
  • [7] [Anonymous], 2021, Global Antimicrobial Resistance and Use Surveillance System (GLASS)
  • [8] Daptomycin Proliposomes for Oral Delivery: Formulation, Characterization, and In Vivo Pharmacokinetics
    Arregui, Javier Rueda
    Kovvasu, Surya Prakasarao
    Betageri, Guru V.
    [J]. AAPS PHARMSCITECH, 2018, 19 (04): : 1802 - 1809
  • [9] Baekkeskov E., 2020, ANTIMICROBIAL RESIST, DOI [10.1093/acrefore/9780190228637.001.0001/acrefore-9780190228637-e-1626, DOI 10.1093/ACREFORE/9780190228637.001.0001/ACREFORE-9780190228637-E-1626]
  • [10] Doxil® - The first FDA-approved nano-drug: Lessons learned
    Barenholz, Yechezkel
    [J]. JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) : 117 - 134